Results 131 to 140 of about 21,301 (157)

Reduced-Dose Dabrafenib-Trametinib for BRAF V600E-Mutant Lung Adenocarcinoma in a Very Elderly Patient With ECOG PS 2. [PDF]

Respirol Case Rep
Suyama S, Sunata K, Uchibori K, Shinomiya S, Tani T, Takahashi S.   +5 more
europepmc   +1 more source

Colorectal neuroendocrine neoplasm organoids reveal the potential therapeutic value of targeting BRAF mutations. [PDF]

J Endocr Soc
Chen Y, Fan B, Zhang Y, Wang Z.
europepmc   +1 more source

Acquired BRAF-AGK Fusion Following Osimertinib Plus Savolitinib in EGFR-Mutated MET-Amplified Non-Small-Cell Lung Cancer: Durable Response to Gefitinib and Trametinib in a Case Report. [PDF]

Onco Targets Ther
Lee AF, Wu SY.
europepmc   +1 more source

Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer. [PDF]

Cell Rep Med
Zeng PYF, Meens J, Karimi AH, Pan H, Cecchini MJ, Jarycki L, Ryan SB, Dawson AE, Shaikh MH, Palma DA, Winquist E, Gunaratnam L, Mymryk JS, Barrett JW, Boutros PC, Ailles L, Nichols AC.   +16 more
europepmc   +1 more source

Efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated advanced thyroid carcinoma: Real world experience in 37 patients. [PDF]

Endocr J
Yamazaki H, Suganuma N, Kadoya M, Masudo K, Matsui A, Saito A.   +5 more
europepmc   +1 more source

Early metastatic <i>BRAF^V600E</i> mutation melanoma without known primary lesion: a case report. [PDF]

Ann Med Surg (Lond)
Wang H, Xu YW, Pan XL, Zhu HH.
europepmc   +1 more source

Correction to "Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma". [PDF]

Mol Oncol
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Anaplastic Thyroid Cancer: Updated Analysis From the Phase II ROAR Basket Study

Annals of Oncology, 2022
J Y Cho, Z A Wainberg, J C Soria
exaly  

Trametinib Versus Standard of Care in Patients With Recurrent Low-Grade Serous Ovarian Cancer (GOG 281/LOGS): An International, Randomised, Open-Label, Multicentre, Phase 2/3 Trial

Lancet, The, 2022
Cs Herrington, Robert L Coleman, David Gershenson   +2 more
exaly  

Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis

Journal of Thoracic Oncology, 2022
Benjamin Besse, Fabrice Barlesi, Tae Min Kim   +2 more
exaly